Unique ID issued by UMIN | UMIN000013852 |
---|---|
Receipt number | R000015675 |
Scientific Title | A phase I/II clinical trial of preoperative carbon-ion radiotherapy and concurrent chemotherapy for stage II or III squamous cell carcinoma of the thoracic esophagus |
Date of disclosure of the study information | 2014/04/30 |
Last modified on | 2024/05/07 12:04:12 |
A phase I/II clinical trial of preoperative carbon-ion radiotherapy and concurrent chemotherapy for stage II or III squamous cell carcinoma of the thoracic esophagus
A phase I/II clinical trial of preoperative carbon-ion radiotherapy and concurrent chemotherapy for stage II or III esophageal squamous cell carcinoma
A phase I/II clinical trial of preoperative carbon-ion radiotherapy and concurrent chemotherapy for stage II or III squamous cell carcinoma of the thoracic esophagus
A phase I/II clinical trial of preoperative carbon-ion radiotherapy and concurrent chemotherapy for stage II or III esophageal squamous cell carcinoma
Japan |
Esophageal cancer
Gastroenterology | Gastrointestinal surgery | Radiology |
Malignancy
NO
To evaluate the safety and therapeutic effect of preoperative carbon-ion radiotherapy and concurrent chemotherapy for stage II or III thoracic esophageal squamous cell carcinoma
Safety,Efficacy
Exploratory
Phase I,II
Acute adverse events
Response rate
Late adverse events
Postoperative complications
Survival rate
Interventional
Single arm
Non-randomized
Open -no one is blinded
Uncontrolled
1
Treatment
Medicine | Device,equipment | Maneuver |
1.Preoperative carbon-ion radiotherapy and concurrent chemotherapy.
Carbon-ion radiotherapy is administered in 8 fractiss over 2 weeks.
Chemothrapy consists of Cisplatin 70 mg/m2/day on days 1 and 22 and 5-FU 700 mg/m2/day on days 1-4 and 22-25.
2.Eesophagectomy and LN dissection is performed within 8weeks after the completion of preoperatve treatment.
20 | years-old | <= |
75 | years-old | >= |
Male and Female
1.Histologically proven squamous cell carcinoma of the thoracic esophagus
2.Clinical stage II or III (sxcluding T4) according to the Japanese classification of esophageal cancer (10th edition)
3.Measurable lesion
4.Age between 20 and 75years old
5.Performance status between 0 and 2
6.Curatively resectable
7.No previous treatments for the esophageal lesion
8.Adequate organ (bone marrow, liver, kidney and so on) functions
9.Written informed consent
1.Past hisotry of radiotherapy in the treatment area
2.Other active cancer
3.Active interstitial pneumonia
4.Active infection in the treatment area
5.HBs-Ag positive, HCV-Ab positive, HIV-Ab positive, HTKLV-1-Ab positive
30
1st name | Hitoshi |
Middle name | |
Last name | Ishikawa |
National Institute for Quantum and Radiological Science and Technology
QST Hospital
263-8555
4-9-1, Anagawa, Inage-ku, Chiba
043-206-3306
ishikawa.hitoshi@qst.go.jp
1st name | Hitoshi |
Middle name | |
Last name | Ishikawa |
National Institute for Quantum and Radiological Science and Technology
QST Hospital
263-8555
4-9-1, Anagawa, Inage-ku, Chiba
043-206-3306
ishikawa.hitoshi@qst.go.jp
National Institute for Quantum and Radiological Science and Technology
National Institute for Quantum and Radiological Science and Technology
Other
National Institutes for Quantum Science and Technology Certified Review Board
4-9-1, Anagawa, Inage-ku, Chiba
043-206-4706
helsinki@qst.go.jp
NO
QST病院
2014 | Year | 04 | Month | 30 | Day |
Unpublished
Completed
2012 | Year | 06 | Month | 08 | Day |
2012 | Year | 06 | Month | 08 | Day |
2012 | Year | 09 | Month | 01 | Day |
2022 | Year | 11 | Month | 02 | Day |
2014 | Year | 04 | Month | 30 | Day |
2024 | Year | 05 | Month | 07 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000015675